PriceTargets.com logo

Ardelyx - ARDX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $10.42
  • Forecasted Upside: 116.11%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$4.82 As of 12/20/2024 06:31 PM ET
▲ +0.13 (2.77%)

This chart shows the closing price for ARDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ardelyx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARDX

Analyst Price Target is $10.42
▲ +116.11% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Ardelyx in the last 3 months. The average price target is $10.42, with a high forecast of $15.00 and a low forecast of $5.50. The average price target represents a 116.11% upside from the last price of $4.82.

This chart shows the closing price for ARDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 contributing investment analysts is to moderate buy stock in Ardelyx. This rating has held steady since October 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/11/2024HC WainwrightDowngradeBuy ➝ Neutral$11.00 ➝ $5.50
11/4/2024CitigroupLower TargetBuy ➝ Buy$12.00 ➝ $10.00
11/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
8/5/2024HC WainwrightBoost TargetBuy ➝ Buy$10.00 ➝ $11.00
8/2/2024CitigroupBoost TargetBuy ➝ Buy$10.00 ➝ $12.00
8/2/2024WedbushReiterated RatingOutperform ➝ Outperform$11.00 ➝ $11.00
7/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00
7/18/2024WedbushReiterated RatingOutperform ➝ Outperform$11.00 ➝ $11.00
7/3/2024CitigroupLower TargetBuy ➝ Buy$14.00 ➝ $10.00
7/2/2024Piper SandlerDowngradeOverweight ➝ Neutral$15.00 ➝ $7.00
6/20/2024Cantor FitzgeraldReiterated RatingOverweight
5/24/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$15.00 ➝ $15.00
5/24/2024WedbushReiterated RatingOutperform ➝ Outperform$15.00 ➝ $15.00
5/3/2024CitigroupBoost TargetBuy ➝ Buy$13.00 ➝ $14.00
5/3/2024WedbushBoost TargetOutperform ➝ Outperform$14.00 ➝ $15.00
4/17/2024WedbushBoost TargetOutperform ➝ Outperform$13.00 ➝ $14.00
4/5/2024Leerink PartnrsReiterated RatingOutperform
4/5/2024Leerink PartnersInitiated CoverageOutperform$14.00
2/23/2024Piper SandlerBoost TargetOverweight ➝ Overweight$12.00 ➝ $15.00
2/23/2024WedbushReiterated RatingOutperform ➝ Outperform$13.00
1/12/2024Cantor FitzgeraldReiterated RatingOverweight
1/12/2024WedbushBoost TargetOutperform ➝ Outperform$9.00 ➝ $13.00
1/10/2024CitigroupBoost TargetBuy ➝ Buy$9.00 ➝ $14.00
1/9/2024Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$12.00 ➝ $15.00
12/18/2023Cantor FitzgeraldReiterated RatingOverweight
12/18/2023Raymond JamesInitiated CoverageStrong-Buy$12.00
12/1/2023WedbushReiterated RatingOutperform ➝ Outperform$9.00
11/1/2023HC WainwrightBoost TargetBuy ➝ Buy$9.00 ➝ $11.00
9/13/2023WedbushReiterated RatingOutperform ➝ Outperform$7.00
9/7/2023HC WainwrightInitiated CoverageBuy ➝ Buy$9.00
8/25/2023Cantor FitzgeraldUpgradeNeutral ➝ Overweight$5.00 ➝ $10.00
8/3/2023LADENBURG THALM/SH SHBoost TargetBuy ➝ Buy$7.50 ➝ $8.50
4/17/2023WedbushBoost TargetOutperform$6.00 ➝ $7.00
3/3/2023WedbushUpgradeNeutral ➝ Outperform$3.00 ➝ $6.00
12/30/2022CitigroupBoost TargetBuy$6.00 ➝ $7.00
12/29/2022Cantor FitzgeraldBoost Target$1.60 ➝ $3.00
11/17/2022Piper SandlerUpgradeNeutral ➝ Overweight$3.00 ➝ $8.00
8/18/2022CitigroupLower Target$12.00 ➝ $10.00
8/5/2022WedbushReiterated RatingNeutral
5/18/2022Piper SandlerLower TargetNeutral$4.00 ➝ $3.00
5/6/2022Cantor FitzgeraldDowngradeOverweight ➝ Neutral$7.00 ➝ $1.00
3/2/2022Jefferies Financial GroupUpgradeHold ➝ Buy$1.00 ➝ $5.00
3/1/2022Cantor FitzgeraldReiterated RatingOverweight
3/1/2022WedbushLower Target$2.00 ➝ $1.00
12/1/2021LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$6.00
11/30/2021CitigroupBoost TargetPositive ➝ Buy$7.00 ➝ $13.00
10/14/2021LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
7/30/2021Cantor FitzgeraldLower TargetOverweight$14.00 ➝ $7.00
7/21/2021CitigroupLower TargetBuy$16.00 ➝ $7.00
7/21/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$11.00 ➝ $2.00
7/20/2021LADENBURG THALM/SH SHBoost TargetBuy$6.50 ➝ $15.00
7/20/2021WedbushDowngradeOutperform ➝ Neutral$3.00
7/20/2021Piper SandlerDowngradeOverweight ➝ Neutral$14.00 ➝ $4.00
7/20/2021CowenSet TargetBuy$7.70
3/22/2021WedbushInitiated CoverageOutperform$14.00
1/5/2021Cantor FitzgeraldInitiated CoverageOverweight$14.00
12/11/2020Leerink PartnersBoost TargetPositive ➝ Outperform$11.00 ➝ $14.00
6/17/2020CowenReiterated RatingBuy
2/18/2020Jefferies Financial GroupReiterated RatingBuy$11.00
2/12/2020CitigroupInitiated CoverageBuy$13.00 ➝ $13.00
2/10/2020CowenInitiated CoverageOutperform
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.16 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 13 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 9 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 9 very positive mentions
  • 10 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 16 very positive mentions
  • 29 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 21 very positive mentions
  • 61 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 12 very positive mentions
  • 60 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 19 very positive mentions
  • 30 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 17 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 17 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Ardelyx logo
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $4.82
Low: $4.58
High: $4.96

50 Day Range

MA: $5.45
Low: $4.50
High: $6.49

52 Week Range

Now: $4.82
Low: $4.32
High: $10.13

Volume

5,041,507 shs

Average Volume

4,893,465 shs

Market Capitalization

$1.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Ardelyx?

The following Wall Street sell-side analysts have issued research reports on Ardelyx in the last year: Cantor Fitzgerald, Citigroup Inc., HC Wainwright, Leerink Partners, Leerink Partnrs, Piper Sandler, Raymond James, StockNews.com, and Wedbush.
View the latest analyst ratings for ARDX.

What is the current price target for Ardelyx?

0 Wall Street analysts have set twelve-month price targets for Ardelyx in the last year. Their average twelve-month price target is $10.42, suggesting a possible upside of 116.1%. Raymond James has the highest price target set, predicting ARDX will reach $15.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.50 for Ardelyx in the next year.
View the latest price targets for ARDX.

What is the current consensus analyst rating for Ardelyx?

Ardelyx currently has 2 hold ratings, 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ARDX.

What other companies compete with Ardelyx?

Other companies that are similar to Ardelyx include Crinetics Pharmaceuticals, Krystal Biotech, Arcellx, ADMA Biologics and Ultragenyx Pharmaceutical. Learn More about companies similar to Ardelyx.

How do I contact Ardelyx's investor relations team?

Ardelyx's physical mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company's listed phone number is (510) 745-1700 and its investor relations email address is [email protected]. The official website for Ardelyx is www.ardelyx.com. Learn More about contacing Ardelyx investor relations.